Ihr Partner für personalisierte Medizin.

Prof. Dr. med. Martin Schostak

Ihr Experte für urologische Onkologie von A-Z.

„Keine Erkrankung und kein Patient sind gleich. Der wichtigste Grundpfeiler meiner Behandlungsphilosophie ist daher die individuelle Auswahl der richtigen Therapie: Von der aktiven Überwachung über eine fokale Therapie bis hin zum chirurgischen Eingriff, einer Bestrahlung oder zur medikamentösen Behandlung. Die Lebenssituation und die individuellen Bedürfnisse des Patienten stehen dabei immer an erster Stelle.“

1996

Promotion an der Charité Berlin

2001-2009

Oberarzt und leitender Oberarzt der Urologischen Klinik der Charité Berlin. Habilitation 2007.

2009-2011

Stellvertretender Direktor der urologischen Klinik der Charité Berlin

2011-2024

Lehrstuhlinhaber und Direktor der Klinik für Urologie, Uroonkologie, robotergestützte und fokale Therapie am Universitätsklinikum Magdeburg

Seit 2025

Geschäftsführer und ärztlicher Leiter der LOGICURO-GmbH

Kürzliche Veröffentlichungen

Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: While this trial has substantial limitations, the results support addition of RP as local therapy to BST in omPC. This trial is registered on ClinicalTrials.gov as NCT02454543.
Weiterlesen >>
Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of the online decision aid was associated with structural improvements, for example, significantly shorter doctor-patient consultation time. Our findings suggest stronger guideline adherence in the counseling process and promotion of health literacy. Successful implementation of our online decision aid in routine care can provide an example for solving this key obstacle for shared decision-making.
Weiterlesen >>
Perioperative Gentamicin Prophylaxis in Robot-Assisted Prostatectomy Increases Acute Kidney Injury Risk
CONCLUSION: The risk of AKI was significantly higher after PAP with gentamicin compared to PAP with cefuroxime (OR: 6.25, 95% CI: 2.095-18.664, p = 0.001), suggesting that PAP with gentamicin should be avoided in RARP.
Weiterlesen >>
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project
CONCLUSIONS AND CLINICAL IMPLICATIONS: TKI-based therapies are applied frequently in pRCC patients. Our data support the use of ICI plus TKI as a first-line standard for patients with pRCC. The major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metastatic pRCC are warranted.
Weiterlesen >>
Comparison of mpMRI and <sup>68</sup>Ga-PSMA-PET/CT in the Assessment of the Primary Tumors in Predominant Low-/Intermediate-Risk Prostate Cancer
While multi-parametric magnetic resonance imaging (mpMRI) is known to be a specific and reliable modality for the diagnosis of non-metastatic prostate cancer (PC), positron emission tomography (PET) using ^(68)Ga labeled ligands targeting the prostate-specific membrane antigen (PSMA) is known for its reliable detection of prostate cancer, being the most sensitive modality for the assessment of the extra-prostatic extension of the disease and the establishment of a diagnosis, even before biopsy....
Weiterlesen >>
Examining the evolving landscape of kidney cancer mortality in the United States
CONCLUSIONS: Over 20 years, the greatest ASMR shifted from AIAN to White individuals, with a nationally decreasing trend. The elderly and male populations continue to experience greater ASMRs. Overall, our findings provide key insights for identifying at-risk populations, guiding the development of targeted strategies to reduce disparities.
Weiterlesen >>
Urologists' Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial
CONCLUSIONS: Physicians are more aware of F2FGs than OSGs. Before COVID-19, F2FGs played a minor role. One out of 4 patients used OSGs. One-third considered them helpful for treatment decision-making. OSG use rarely affects the final treatment decision. Urologists significantly underestimate OSG use by their patients. Peer-to-peer support is more likely to be received by patients with anxiety and depression. Comparative interventional trials are needed to recommend peer-to-peer interventions for...
Weiterlesen >>
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: The use of microultrasonography-guided biopsy was noninferior to MRI/conventional ultrasonography fusion-guided biopsy for the detection of Gleason Grade Group 2 or higher prostate cancer in biopsy-naive men. Microultrasonography may provide an alternative to MRI for image-guided prostate biopsy.
Weiterlesen >>
Active surveillance of prostate cancer
The aim of active surveillance (AS) is to avoid overtreatment of clinically insignificant prostate cancer (PCa). It is now strongly recommended for patients diagnosed with localized low-risk PCa. Additionally, it can be considered for selected patients with localized PCa in the International Society of Urological Pathology (ISUP) group 2, provided patients have a favorable risk profile. This profile is histopathologically characterized by the presence of a low percentage of Gleason pattern 4 and...
Weiterlesen >>
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL did not significantly differ between the biweekly CBZ16 and the standard schedule. Additionally, onset of some adverse events was delayed. These results may increase health care providers' confidence in using CBZ in older patients with mCRPC who are denied chemotherapy.
Weiterlesen >>
prev next

Kürzliche Veröffentlichungen

Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: While this trial has substantial limitations, the results support addition of RP as local therapy to BST in omPC. This trial is registered on ClinicalTrials.gov as NCT02454543.
Weiterlesen >>
Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of the online decision aid was associated with structural improvements, for example, significantly shorter doctor-patient consultation time. Our findings suggest stronger guideline adherence in the counseling process and promotion of health literacy. Successful implementation of our online decision aid in routine care can provide an example for solving this key obstacle for shared decision-making.
Weiterlesen >>
Perioperative Gentamicin Prophylaxis in Robot-Assisted Prostatectomy Increases Acute Kidney Injury Risk
CONCLUSION: The risk of AKI was significantly higher after PAP with gentamicin compared to PAP with cefuroxime (OR: 6.25, 95% CI: 2.095-18.664, p = 0.001), suggesting that PAP with gentamicin should be avoided in RARP.
Weiterlesen >>
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project
CONCLUSIONS AND CLINICAL IMPLICATIONS: TKI-based therapies are applied frequently in pRCC patients. Our data support the use of ICI plus TKI as a first-line standard for patients with pRCC. The major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metastatic pRCC are warranted.
Weiterlesen >>
Comparison of mpMRI and <sup>68</sup>Ga-PSMA-PET/CT in the Assessment of the Primary Tumors in Predominant Low-/Intermediate-Risk Prostate Cancer
While multi-parametric magnetic resonance imaging (mpMRI) is known to be a specific and reliable modality for the diagnosis of non-metastatic prostate cancer (PC), positron emission tomography (PET) using ^(68)Ga labeled ligands targeting the prostate-specific membrane antigen (PSMA) is known for its reliable detection of prostate cancer, being the most sensitive modality for the assessment of the extra-prostatic extension of the disease and the establishment of a diagnosis, even before biopsy....
Weiterlesen >>
Examining the evolving landscape of kidney cancer mortality in the United States
CONCLUSIONS: Over 20 years, the greatest ASMR shifted from AIAN to White individuals, with a nationally decreasing trend. The elderly and male populations continue to experience greater ASMRs. Overall, our findings provide key insights for identifying at-risk populations, guiding the development of targeted strategies to reduce disparities.
Weiterlesen >>
Urologists' Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial
CONCLUSIONS: Physicians are more aware of F2FGs than OSGs. Before COVID-19, F2FGs played a minor role. One out of 4 patients used OSGs. One-third considered them helpful for treatment decision-making. OSG use rarely affects the final treatment decision. Urologists significantly underestimate OSG use by their patients. Peer-to-peer support is more likely to be received by patients with anxiety and depression. Comparative interventional trials are needed to recommend peer-to-peer interventions for...
Weiterlesen >>
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: The use of microultrasonography-guided biopsy was noninferior to MRI/conventional ultrasonography fusion-guided biopsy for the detection of Gleason Grade Group 2 or higher prostate cancer in biopsy-naive men. Microultrasonography may provide an alternative to MRI for image-guided prostate biopsy.
Weiterlesen >>
Active surveillance of prostate cancer
The aim of active surveillance (AS) is to avoid overtreatment of clinically insignificant prostate cancer (PCa). It is now strongly recommended for patients diagnosed with localized low-risk PCa. Additionally, it can be considered for selected patients with localized PCa in the International Society of Urological Pathology (ISUP) group 2, provided patients have a favorable risk profile. This profile is histopathologically characterized by the presence of a low percentage of Gleason pattern 4 and...
Weiterlesen >>
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL did not significantly differ between the biweekly CBZ16 and the standard schedule. Additionally, onset of some adverse events was delayed. These results may increase health care providers' confidence in using CBZ in older patients with mCRPC who are denied chemotherapy.
Weiterlesen >>
prev next

Expertise

Chirurgische Eingriffe

Weitreichende Erfahrung durch tausende offene, laparoskopische und robotergestützte Eingriffe an Prostata, Niere und Harnblase.

Fokale und Mikrotherapie

Vorsitzender des Arbeitskreises für Fokale und Mikrotherapie der Akademie der deutschen Urologen.

Medikamentöse Tumortherapie

Diverse Zusatzqualifikationen für eine Vielzahl moderner, medikamentenbasierter Tumorbehandlungen.

Leitliniengerechte Behandlung

Mitgestaltung der Best-Practices als langjähriger Angehöriger der S3-Leitlinienkommission für Prostatakrebs.

Management klinischer Studien

Durchführung und Leitung zahlreicher wissenschaftlicher Studien mit internationaler Ausprägung.

Medizinische Forschung

Über 240 peer-review Publikationen mit über 4500 Zitierungen. Reviewer für zahlreiche Fachzeitschriften.

Uroonkologische Studienzentrale

Die uroonkologische Studienzentrale der LOGICURO GmbH ist eine außeruniversitäre Forschungseinrichtung in Potsdam.

Unter der Leitung von Prof. Schostak führt das Team Phase-II- und Phase-III-Studien zu medikamentösen Therapien bei uroonkologischen Tumoren durch.

Die systemische Therapie urologischer Tumoren hat in den vergangenen zehn Jahren eine bemerkenswerte Entwicklung erfahren: Zahlreiche neue Wirkstoffe sind bereits zugelassen, weitere befinden sich in fortgeschrittener klinischer Prüfung.

Unser Anspruch ist es, wissenschaftliche Exzellenz mit langjähriger klinischer Expertise zu verbinden – um innovative Therapieoptionen frühzeitig für die Patientinnen und Patienten im südwestlichen Teil der Metropolregion Berlin & Potsdam verfügbar zu machen.

Privatpraxis

LOGICURO bietet im Rahmen der Privatpraxis von Prof. Schostak eine spezialisierte urologische Beratung außerhalb der Routineversorgung an.
Der Focus liegt auf einer strukturierten ärztlichen Einordnung bei komplexen Fragestellungen, insbesondere bei urologischen Tumorerkrankungen.

Besondere Schwerpunkte von Prof. Schostak

  • Unterstützung bei schwierigen oder offenen Therapieentscheidungen, z. B. bei der Abwägung zwischen unterschiedlichen Behandlungsoptionen oder einem abwartenden Vorgehen
  • Strukturierte Einordnung, wenn mehrere therapeutische Strategien in Betracht kommen
  • Medizinische Bewertung bei unklarer oder kontroverser Datenlage
  • Beratung zu erweiterten Therapieoptionen, einschließlich neuer Konzepte wie z. B. fokale Therapie und klinische Studien
  • Leitliniengerechte Zweitmeinungen bei fortgeschrittenen urologischen Tumorerkrankungen

Medizinische Entscheidungen sollen gut informiert, nachvollziehbar und – soweit sinnvoll – gemeinsam getroffen werden. Grundlage sind aktuelle wissenschaftliche Erkenntnisse sowie eine langjährige klinische Erfahrung in der Uroonkologie.

Beratung & Zweitmeinung

  • Unabhängige, strukturierte ärztliche Zweitmeinung, insbesondere bei urologischen Krebserkrankungen (Prostata, Blase, Niere).
    Sinnvoll bei mehreren Therapieoptionen, unklaren Befunden oder vor weitreichenden Behandlungsentscheidungen.

Labor & Ultraschall

  • Gezielte labormedizinische Untersuchungen und urologische Ultraschalldiagnostik zur ergänzenden diagnostischen Einordnung im Rahmen einer Beratung oder Zweitmeinung.

Medikamentöse Tumortherapie

  • Prüfung und Einordnung medikamentöser Therapieoptionen im Rahmen einer strukturierten Beratung.
    Medikamentöse Tumortherapie im Rahmen klinischer Prüfungen.

Für eine effiziente und sorgfältige Beratung bitten wir Sie, folgende Unterlagen in Kopie mitzubringen:

  • alle relevanten Arztbriefe und Befunde
  • aktuelle Laborergebnisse
  • CDs mit relevanten Bildgebungen (z. B. CT, MRT, PET-CT)

  • unabhängige Beratung ohne Zeitdruck
  • hohe uroonkologische Expertise
  • verständliche Einordnung komplexer medizinischer Sachverhalte
  • gemeinsame, informierte Therapieentscheidungen

Zweitmeinung, Beratung oder Anfrage?

Nehmen Sie jetzt Kontakt auf!

Hier finden Sie unsere Studienzentrale:

Alt Nowawes 65 (Besuchereingang)
Alt Nowawes 67 (Post)
14482 Potsdam

Studienzentrale